COVID-19 Therapeutics and Vaccines: A Race to Save Lives | Zendy

Ilona Bebenek | Zendy; Roy Bannister | Zendy; John Dubinion | Zendy; Marie Fortin | Zendy; Matt Liu | Zendy; Arianne L. Motter | Zendy; Cynthia M. Rohde | Zendy; Claudia Wrzesinski | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

COVID-19 Therapeutics and Vaccines: A Race to Save Lives

Author(s) -

Ilona Bebenek,

Roy Bannister,

John Dubinion,

Marie Fortin,

Matt Liu,

Arianne L. Motter,

Cynthia M. Rohde,

Claudia Wrzesinski

Publication year - 2021

Publication title -

toxicological sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.352

H-Index - 183

eISSN - 1096-6080

pISSN - 1096-0929

DOI - 10.1093/toxsci/kfab130

Subject(s) - covid-19 , medicine , food and drug administration , intensive care medicine , coronavirus , disease , clinical trial , public health , virology , immunology , medical emergency , infectious disease (medical specialty) , outbreak , pathology

COVID-19 (Coronavirus Disease 2019), the disease caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) is an ongoing global public health emergency. As understanding of the health effects of COVID-19 has improved, companies and agencies worldwide have worked together to identify therapeutic approaches, fast-track clinical trials and pathways for emergency use, and approve therapies for patients. This work has resulted in therapies that not only improve survival, reduce time of hospitalization, and time to recovery, but also include preventative measures, such as vaccines. This manuscript discusses development programs for 3 products that are approved or authorized for emergency use at the time of writing: VEKLURY (remdesivir, direct-acting antiviral from Gilead Sciences, Inc.), REGEN-COV (casirivimab and imdevimab antibody cocktail from Regeneron Pharmaceuticals Inc.), and Comirnaty (Pfizer-BioNTech COVID-19 Vaccine [Pfizer, Inc.-BioNTech]), and perspectives from the U.S. Food and Drug Administration.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research